SG Americas Securities LLC boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 632.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,545 shares of the biotechnology company’s stock after purchasing an additional 10,832 shares […]
Nisa Investment Advisors LLC trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 16.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,361 shares of the biotechnology company’s stock after selling 3,830 shares during the period. Nisa […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) had its price objective increased by research analysts at Robert W. Baird from $112.00 to $127.00 in a report released on Thursday, The Fly reports. Robert W. Baird’s price target points to a potential upside of 36.56% from the company’s current price. Other equities research analysts have also recently […]
Mesirow Institutional Investment Management Inc. increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 5.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,980 shares of the biotechnology company’s stock after acquiring an additional 1,200 shares during the quarter. Mesirow […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) issued an update on its FY23 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $1.80-2.05 for the period, compared to the consensus estimate of $1.98. The company issued revenue guidance of $2.375-2.500 billion, compared to the consensus revenue estimate of $2.46 billion. BioMarin […]